Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Amonkar

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Current Medical Research and Opinion|March 11, 2010
Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancerB Kaufman, Y Wu, M M Amonkar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerY Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2011
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerY Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJ-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyD Schadendorf, M M Amonkar, M Milhem, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Current Medical Research and Opinion|March 11, 2010
Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancerB Kaufman, Y Wu, M M Amonkar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerY Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2011
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerY Wu, M M Amonkar, B H Sherrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJ-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyD Schadendorf, M M Amonkar, M Milhem, et al.
Pageof 2